Hospital certification
Announcement on Certified Medical Institutions Authorized to Administer Carteyva® (Relmacabtagene Autoleucel Injection)
- On September 1, 2021, Carteyva(Relmacabtagene Autoleucel Injection), a CAR-T cell therapy developed by Shanghai JW Therapeutics Co., Ltd., was approved by the National Medical Products Administration (NMPA) of medical institutions that have completed the required training and certification for the administration of Carteyva®provided below.
- Link:List of Certified Medical Institutions
- The list will be updated periodically as additional medical institutions complete the required training and certification
Medical Representative Registration Information
- In accordance with the Administrative Measures for the Registration of (Trial), Shanghai JW Therapeutics Co., Ltd. hasMedical Representativesregistered the relevant information of its medical representatives on the registration platform designated by the National Medical Products Administration (NMPA).
- To search the registration information of our medical representatives, please visit the official platform below.
- https://pharmareps.cpa.org.cn/reception/index